The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
2019
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
- Ist Teil von
- Nature nanotechnology, 2019-12, Vol.14 (12), p.1084-1087
- Ort / Verlag
- England: Nature Publishing Group
- Erscheinungsjahr
- 2019
- Quelle
- Springer Nature - Connect here FIRST to enable access
- Beschreibungen/Notizen
- The regulatory approval of Onpattro, a lipid nanoparticle-based short interfering RNA drug for the treatment of polyneuropathies induced by hereditary transthyretin amyloidosis, paves the way for clinical development of many nucleic acid-based therapies enabled by nanoparticle delivery.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1748-3387eISSN: 1748-3395DOI: 10.1038/s41565-019-0591-yTitel-ID: cdi_proquest_miscellaneous_2322143083
- Format
- –
- Schlagworte
- Amyloidosis, Animals, Drug Approval, Drug Carriers - chemistry, Drug Delivery Systems, Drug Development, Humans, Lipids, Nanomedicine, Nanoparticles, Nanoparticles - chemistry, Polyneuropathies - drug therapy, Regulatory approval, Ribonucleic acid, RNA, RNA, Small Interfering - administration & dosage, RNA, Small Interfering - chemistry, RNA, Small Interfering - therapeutic use, siRNA, Translational Medical Research, Transthyretin